Ellen H. Van Der Spek

Arnhem, GE, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Challenges in predicting outcomes for watch and wait follicular lymphoma patients: insights into clinical, pathological, and molecular factors.

Challenges in predicting outcomes for watch and wait follicular lymphoma patients: insights into clinical, pathological, and molecular factors.

Journal: Leukemia & lymphoma

Published: October 14, 2025

Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome.

Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome.

Journal: HemaSphere

Published: July 31, 2025

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.

Journal: Blood advances

Published: June 09, 2025

Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial.

Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Haematology

Published: June 06, 2025

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels.

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels.

Journal: HemaSphere

Published: March 17, 2025

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma.

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma.

Journal: Blood

Published: June 25, 2024

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.

Journal: HemaSphere

Published: February 16, 2024

Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.

Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.

Journal: American journal of hematology

Published: January 07, 2024

Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma.

Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma.

Journal: HemaSphere

Published: June 27, 2023

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.

Journal: American journal of hematology

Published: June 25, 2023

Hematologists/Physicians Need to Be Aware of Pseudohypercalcemia in Monoclonal Gammopathy: Lessons from a Case Report.

Hematologists/Physicians Need to Be Aware of Pseudohypercalcemia in Monoclonal Gammopathy: Lessons from a Case Report.

Journal: Case reports in hematology

Published: June 22, 2023

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.

Journal: EClinicalMedicine

Published: May 14, 2023

Showing 1-12 of 36

Last Updated: 09/26/2026